Supernus Pharmaceuticals Inc

SUPN

Equity

ISIN null / Valor 18393960

NASDAQ (2025-11-21)

USD 45.32+1.18%

Supernus Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Supernus Pharmaceuticals Inc is a biopharmaceutical company with over 30 years of experience specializing in developing and commercializing products for the treatment of central nervous system (CNS) diseases. Their portfolio includes a range of therapeutic categories aimed at providing significant health benefits to patients suffering from CNS diseases.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Net sales for Qelbree® surged by 44% to $64.7 million, while GOCOVRI® saw a 16% increase to $30.7 million compared to the same period in 2024. Overall, total revenues rose by 4% to $149.8 million, with non-GAAP revenues excluding Trokendi XR® and Oxtellar XR® increasing by 26% year-over-year.

Operating Performance

The company reported an operating loss of $(10.3) million for the first quarter of 2025, up from $(3.2) million in 2024. However, adjusted operating earnings on a non-GAAP basis improved by 16%, reaching $25.9 million.

Product Launch and Prescriptions

In April 2025, Supernus launched ONAPGO™, the first subcutaneous apomorphine infusion device for advanced Parkinson’s disease, receiving encouraging early physician feedback. Additionally, Qelbree® prescriptions increased by 22% to 214,908, with total monthly prescriptions hitting an all-time high of 75,277 in March 2025.

Financial Position and Guidance

As of March 31, 2025, the company held approximately $463.6 million in cash, cash equivalents, and marketable securities, up from $453.6 million at the end of 2024. Supernus reiterated its full-year 2025 financial guidance, emphasizing continued growth and strategic investments.

Summarized from source with an LLMView Source

Key figures

26.5%1Y

30.9%3Y

118%5Y

Performance

35.5%1Y

34.7%3Y

38.3%5Y

Volatility